Drug interactions in patients affected by cardiovascular disease
International Journal of Development Research
Drug interactions in patients affected by cardiovascular disease
Received 20th September, 2020; Received in revised form 04th October, 2020; Accepted 28th November, 2020; Published online 31st December, 2020
Copyright © 2020, Lúcia Helena Almeida Gratão et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This work aims to analyze the possible drug interactions in adults and elderly people with manifest atherosclerotic disease. Fifty patients were enrolled in the multi-center study of the Brazilian Cardioprotective Food Program, UFT, Palmas, Tocantins. The Drugdex (MicroMedex) and Med Tap software databases and the Drug Interactions website were used. We obtained an average of 6.4 medications per individual, and we observed the incidence of clinically relevant interactions such as Clopidogrel with AAS 38% and Enalapril with AAS 26%. Potentially dangerous interactions in clinical practice, such as Clopidogrel with ASA, can present health risks to patients and may even lead to death. Different interections were observed, from light to severe levels, thus requiring better care by the multi-professional health team with this type of patient, since these interactions may lead to greater appearance of side effects or loss effects of the drugs so necessary for the treatment of these individuals.
